SLN241115P17500
- 0.00
- 0.000.00%
Silence Therapeutics Newsroom
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely
Express News | Silence Therapeutics - From Time to Time, Co or Any Selling Shareholder May Offer and Sell Ordinary Shares
Express News | Silence Therapeutics PLC Files for Stock Shelf; Size Not Disclosed - SEC Filing
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
AstraZeneca Deal Has Positive Read for Silence Therapeutics, Says Morgan Stanley
Silence Therapeutics Insider Ups Holding During Year
Jefferies Initiates Silence Therapeutics(SLN.US) With Buy Rating, Announces Target Price $40
Silence Therapeutics Analyst Ratings
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Silence Therapeutics: Strong Buy on Underappreciated Blockbuster Potential and Clinical Advancements
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Pharvaris (PHVS) and Stevanato Group (STVN)
Morgan Stanley Reaffirms Their Buy Rating on Silence Therapeutics (SLN)
More Unpleasant Surprises Could Be In Store For Silence Therapeutics Plc's (NASDAQ:SLN) Shares After Tumbling 26%
Silence Therapeutics Second Quarter 2024 Earnings: Misses Expectations
Analyst Expectations For Silence Therapeutics's Future
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $67
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $55 Price Target